Orthofix Medical, Inc. (OFIX)

NASDAQHealth CareMedical - DevicesSnapshot 2026-10-23

$9.81-1.80%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Orthofix Medical, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	233.19M
EPS	—	0.032
FY 2026 · Annual
Revenue	$850M–$860M	851.2M
EPS	—	-1.175
FY 2027 · Annual
Revenue	—	873.64M
EPS	—	-0.945

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Positive free cash flow in 2026	The company targets positive free cash flow this year.	Improving	free cash flow remains negative through FY26	Free cash flow: $-18.871M FY2026-Q2; GAAP. Published target: >0. Target period is not explicitly aligned with this observation. Source published Aug 5, 2026-18,871,000 USD · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Management consistently expects positive free cash flow for full-year 2026 excluding legal settlements. However, actual cash from operations was negative $17.6M in 2026-Q1 and negative $17.6M in 2026-Q2, indicating limited progress toward positive free cash flow so far. Delivery assessment Oct 24, 2026
Stable management and execution	A supporting condition in Orthofix Medical, Inc.'s published investment case. The stated target is no major negative leadership changes.	Under Pressure	significant executive departures or governance issues arise	1 executive departure (President, Global Spine) vs 0 major negative changes News and events confirm the departure of the President of Global Spine, a key executive role, indicating leadership instability. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Achieve $838M to $848M revenue in 2026	A primary condition in Orthofix Medical, Inc.'s published investment case. The stated target is ~$843M.	Intact	annual revenue falls below $810M in FY26	Revenue: $210.933M FY2026-Q2; GAAP. Published target: ~$843M. Target period is not explicitly aligned with this observation. Source published Aug 5, 2026210,933,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: c9e1af1b-599d-49fd-a36d-d27654d5063d. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenueUnavailable

Unavailable → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	1 / 4
2026-07-25	Unavailable	Unavailable	1 / 4
2026-07-26	Unavailable	$885,701,400	2 / 5
2026-07-27	Unavailable	Unavailable	1 / 4
2026-07-28	Unavailable	$885,701,400	2 / 5
2026-07-29	Unavailable	$885,701,400	2 / 5
2026-07-30	Unavailable	$885,701,400	2 / 5
2026-07-31	Unavailable	Unavailable	1 / 4
2026-08-01	Unavailable	Unavailable	1 / 4
2026-08-02	Unavailable	$885,701,400	2 / 5
2026-08-03	Unavailable	Unavailable	1 / 4
2026-08-04	Unavailable	Unavailable	1 / 4
2026-08-05	Unavailable	Unavailable	1 / 4
2026-08-06	Unavailable	Unavailable	1 / 4
2026-08-07	Unavailable	Unavailable	1 / 4
2026-08-08	Unavailable	$877,410,400	2 / 5
2026-08-09	Unavailable	$877,410,400	2 / 5
2026-08-10	Unavailable	Unavailable	1 / 4
2026-08-12	Unavailable	Unavailable	1 / 4
2026-08-13	Unavailable	$871,914,000	1 / 5
2026-08-14	Unavailable	Unavailable	1 / 4
2026-08-15	Unavailable	Unavailable	1 / 4
2026-08-16	Unavailable	Unavailable	1 / 4
2026-08-17	Unavailable	Unavailable	1 / 4
2026-08-18	Unavailable	Unavailable	1 / 4
2026-08-19	Unavailable	Unavailable	1 / 4
2026-08-20	Unavailable	Unavailable	1 / 4
2026-08-21	Unavailable	Unavailable	1 / 4
2026-08-22	Unavailable	Unavailable	1 / 4
2026-08-23	Unavailable	Unavailable	1 / 4
2026-08-24	Unavailable	Unavailable	1 / 4
2026-08-25	Unavailable	Unavailable	1 / 4
2026-08-26	Unavailable	Unavailable	1 / 4
2026-08-27	Unavailable	Unavailable	1 / 4
2026-08-28	Unavailable	Unavailable	1 / 4
2026-08-29	Unavailable	Unavailable	1 / 4
2026-08-30	Unavailable	Unavailable	1 / 4
2026-08-31	Unavailable	Unavailable	1 / 4
2026-09-01	Unavailable	Unavailable	1 / 4
2026-09-02	Unavailable	Unavailable	1 / 4
2026-09-03	Unavailable	Unavailable	1 / 4
2026-09-04	Unavailable	Unavailable	1 / 4
2026-09-05	Unavailable	Unavailable	1 / 4
2026-09-06	Unavailable	Unavailable	1 / 4
2026-09-07	Unavailable	Unavailable	1 / 4
2026-09-08	Unavailable	Unavailable	1 / 4
2026-09-09	Unavailable	Unavailable	1 / 4
2026-09-10	Unavailable	Unavailable	1 / 4
2026-09-11	Unavailable	Unavailable	1 / 4
2026-09-12	Unavailable	Unavailable	1 / 4
2026-09-13	Unavailable	Unavailable	1 / 4
2026-09-14	Unavailable	Unavailable	1 / 4
2026-09-15	Unavailable	Unavailable	1 / 4
2026-09-16	Unavailable	Unavailable	1 / 4
2026-09-17	Unavailable	Unavailable	1 / 4
2026-09-18	Unavailable	Unavailable	1 / 4
2026-09-19	Unavailable	Unavailable	1 / 4
2026-09-20	Unavailable	Unavailable	1 / 4
2026-09-21	Unavailable	Unavailable	1 / 4
2026-09-22	Unavailable	Unavailable	1 / 4
2026-09-23	Unavailable	Unavailable	1 / 4
2026-09-24	Unavailable	Unavailable	1 / 4
2026-09-25	Unavailable	Unavailable	1 / 4
2026-09-26	Unavailable	Unavailable	1 / 4
2026-09-27	Unavailable	Unavailable	1 / 4
2026-09-28	Unavailable	Unavailable	1 / 4
2026-09-29	Unavailable	Unavailable	1 / 4
2026-09-30	Unavailable	Unavailable	1 / 4
2026-10-01	Unavailable	Unavailable	1 / 4
2026-10-02	Unavailable	Unavailable	1 / 4
2026-10-03	Unavailable	Unavailable	1 / 4
2026-10-04	Unavailable	Unavailable	1 / 4
2026-10-05	Unavailable	Unavailable	1 / 4
2026-10-06	Unavailable	Unavailable	1 / 4
2026-10-07	Unavailable	Unavailable	1 / 4
2026-10-08	Unavailable	Unavailable	1 / 4
2026-10-09	Unavailable	Unavailable	1 / 4
2026-10-10	Unavailable	Unavailable	1 / 4
2026-10-11	Unavailable	Unavailable	1 / 4
2026-10-12	Unavailable	Unavailable	1 / 4
2026-10-13	Unavailable	Unavailable	1 / 4
2026-10-14	Unavailable	Unavailable	1 / 4
2026-10-15	Unavailable	Unavailable	1 / 4
2026-10-16	Unavailable	Unavailable	1 / 4
2026-10-17	Unavailable	Unavailable	1 / 4
2026-10-18	Unavailable	Unavailable	1 / 4
2026-10-19	Unavailable	Unavailable	1 / 3
2026-10-20	Unavailable	Unavailable	1 / 3
2026-10-21	Unavailable	Unavailable	1 / 3
2026-10-22	Unavailable	Unavailable	1 / 3
2026-10-23	Unavailable	Unavailable	1 / 3
2026-10-24	Unavailable	Unavailable	1 / 3

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	3	2
2026-06-01	3	2
2026-07-01	3	2
2026-08-01	3	2
2026-09-01	3	2
2026-10-01	3	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 3 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Positive free cash flow in 2026Free cash flow: $-18.871M
Stable management and executionPublished status: Under Pressure
Achieve $838M to $848M revenue in 2026Revenue: $210.933M

Next proof point

Nov 3, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.1%Typical daily move · historical

Downside history

-46.7%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Orthofix Medical, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a higher-risk growth and profitability improvement story, not yet a proven earnings compounder, because the company is loss-making. The long-term thesis is intact, with management priorities on revenue and adjusted EBITDA on track, but cash generation remains mixed.

What's priced into Orthofix Medical, Inc.

The snapshot describes OFIX as cheap versus peers, while also tagging expectations as justified and reporting low valuation-model confidence. That points to a valuation discount without clear evidence that the market is assuming an unusually strong outcome.

What the fundamentals likely do

Near term, recent earnings beats and slightly higher 2026 revenue guidance support continued growth, and adjusted EBITDA progress is described as steady. The main execution gap is cash flow: operating cash flow was negative in both the first and second quarters, despite management’s full-year positive free-cash-flow goal excluding legal settlements. Risk is elevated, and a guidance reversal or weaker employment data could weigh on the business outlook.

What Orthofix Medical, Inc. hinges on

Over the next few quarters, the thesis depends on delivering the 2026 revenue and adjusted EBITDA goals while improving cash generation. A guidance cut after the recent increase would damage confidence; continued strength from healthcare peers could support the sector backdrop, while weaker jobs data could add recession concerns.